ACR Convergence 2023 Highlights: Two Studies: TAK-279 (Tyk2) in PsA and Apremilast MRI Study in PsA | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

RheumNow

ACR Convergence 2023 Highlights: Two Studies: TAK-279 (Tyk2) in PsA and Apremilast MRI Study in PsA

By RheumNow FEATURING Guillermo Valenzuela

By RheumNow FEATURING Guillermo Valenzuela

190 views

December 14, 2023

The above content is not sponsored by, nor part of, the American College of Rheumatology.

Comments 0

Login to view comments. Click here to Login